Search

Your search keyword '"A, Masson-Lecomte"' showing total 252 results
Start Over Author "A, Masson-Lecomte" Publication Year Range Last 3 years
252 results on '"A, Masson-Lecomte"'

2. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R. M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Contieri, Roberto, Mertens, Laura S., Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A. L. M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N’Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas W. G.

Published
2024
Full Text
View/download PDF

6. Patients non répondeurs au BCG

Author

Leon, Priscilla, Pradère, Benjamin, Neuzillet, Yann, Bajeot, Anne Sophie, Marcq, Gautier, Prost, Doriane, Thibault, Constance, Xylinas, Evanguelos, Allory, Yves, Audenet, François, Masson-Lecomte, Alexandra, Seisen, Thomas, Rouprêt, Morgan, and Roumiguié, Mathieu

Published
2024
Full Text
View/download PDF

7. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels

Author

Mertens, Laura S., Bruins, Harman Maxim, Contieri, Roberto, Babjuk, Marek, Rai, Bhavan P., Puig, Albert Carrión, Escrig, Jose Luis Dominguez, Gontero, Paolo, van der Heijden, Antoine G., Liedberg, Fredrik, Martini, Alberto, Masson-Lecomte, Alexandra, Meijer, Richard P., Mostafid, Hugh, Neuzillet, Yann, Pradere, Benjamin, Redlef, John, van Rhijn, Bas W.G., Rouanne, Matthieu, Rouprêt, Morgan, Sæbjørnsen, Sæbjørn, Seisen, Thomas, Shariat, Shahrokh F., Soria, Francesco, Soukup, Viktor, Thalmann, George, Xylinas, Evanguelos, Mariappan, Paramananthan, and Alfred Witjes, J.

Published
2024
Full Text
View/download PDF

11. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

Author

Irene J. Beijert, Liang Cheng, Fredrik Liedberg, Karin Plass, Sean R. Williamson, Paolo Gontero, Maria J. Ribal, Marko Babjuk, Peter C. Black, Ashish M. Kamat, Ferran Algaba, David M. Berman, Arndt Hartmann, Alexandra Masson-Lecomte, Morgan Rouprêt, Antonio Lopez-Beltran, Hemamali Samaratunga, Shahrokh F. Shariat, A. Hugh Mostafid, Murali Varma, Steven Shen, Maximilian Burger, Toyonori Tsuzuki, Joan Palou, Eva M. Compérat, Richard J. Sylvester, Theo H. van der Kwast, Bas W.G. van Rhijn, and Michelle R. Downes

Subjects
Bladder, Cancer, Grading, Survey, European Association of Urology, International Society of Urological Pathology, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary urothelial neoplasm of low malignant potential [PUNLMP], low-grade [LG], high-grade [HG] carcinoma) are used. Objective: To ask the European Association of Urology (EAU) and International Society of Urological Pathology (ISUP) members regarding their current practice and preferences of grading systems. Design, setting, and participants: A web-based, anonymous questionnaire with ten questions on grading of NMIBC was created. The members of EAU and ISUP were invited to complete an online survey by the end of 2021. Thirteen experts had previously answered the same questions. Outcome measurements and statistical analysis: The submitted answers from 214 ISUP members, 191 EAU members, and 13 experts were analyzed. Results and limitations: Currently, 53% use only the WHO2004 system and 40% use both systems. According to most respondents, PUNLMP is a rare diagnosis with management similar to Ta-LG carcinoma. The majority (72%) would consider reverting back to WHO1973 if grading criteria were more detailed. Separate reporting of WHO1973-G3 within WHO2004-HG would influence clinical decisions for Ta and/or T1 tumors according the majority (55%). Most respondents preferred a two-tier (41%) or a three-tier (41%) grading system. The current WHO2004 grading system is supported by a minority (20%), whereas nearly half (48%) supported a hybrid three- or four-tier grading system composed of both WHO1973 and WHO2004. The survey results of the experts were comparable with ISUP and EAU respondents. Conclusions: Both the WHO1973 and the WHO2004 grading system are still widely used. Even though opinions on the future of bladder cancer grading were strongly divided, there was limited support for WHO1973 and WHO2004 in their current formats, while the hybrid (three-tier) grading system with LG, HG-G2, and HG-G3 as categories could be considered the most promising alternative. Patient summary: Grading of non–muscle-invasive bladder cancer (NMIBC) is a matter of ongoing debate and lacks international consensus. We surveyed urologists and pathologists of European Association of Urology and International Society of Urological Pathology on their preferences regarding NMIBC grading to generate a multidisciplinary dialogue. Both the “old” World Health Organization (WHO) 1973 and the “new” WHO2004 grading schemes are still used widely. However, continuation of both the WHO1973 and the WHO2004 system showed limited support, while a hybrid grading system composed of both the WHO1973 and the WHO2004 classification system may be considered a promising alternative.

Published
2023
Full Text
View/download PDF

14. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures

Author

Fontugne, Jacqueline, Xylinas, Evanguelos, Krucker, Clémentine, Dixon, Victoria, Groeneveld, Clarice S., Pinar, Ugo, Califano, Gianluigi, Bucau, Margot, Verine, Jérôme, Desgrandchamps, François, Hermieu, Jean-François, Radvanyi, François, Allory, Yves, and Masson-Lecomte, Alexandra

Published
2023
Full Text
View/download PDF

15. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies

Author

Laura S. Mertens, Vidit Sharma, Surena F. Matin, Stephen A. Boorjian, R. Houston Thompson, Bas W.G. van Rhijn, and Alexandra Masson-Lecomte

Subjects
Urothelial cancer, Upper tract, Bladder recurrence, Nephroureterectomy, Ureterorenoscopy, Intravesical instillation, Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Context: Bladder recurrences have been reported in 22–47% of patients after surgery for upper urinary tract urothelial carcinoma (UTUC). This collaborative review focuses on risk factors for and treatment strategies to reduce bladder recurrences after upper tract surgery for UTUC. Objective: To review the current evidence on risk factors and treatment strategies for intravesical recurrence (IVR) after upper tract surgery for UTUC. Evidence acquisition: This collaborative review is based on a literature search of PubMed/Medline, Embase, Cochrane Library, and currently available guidelines on UTUC. Relevant papers on bladder recurrence (etiology, risk factors, and management) after upper tract surgery were selected. Special attention has been paid to (1) the genetic background of bladder recurrences, (2) bladder recurrences after ureterorenoscopy (URS) with or without a biopsy, and (3) postoperative or adjuvant intravesical instillations. The literature search was performed in September 2022. Evidence synthesis: Recent evidence supports the hypothesis that bladder recurrences after upper tract surgery for UTUC are often clonally related. Clinicopathologic risk factors (patient, tumor, and treatment related) have been identified for bladder recurrences after UTUC diagnosis. Specifically, the use of diagnostic ureteroscopy before radical nephroureterectomy (RNU) is associated with an increased risk of bladder recurrences. Further, a recent retrospective study suggests that performing a biopsy during ureteroscopy may further worsen IVR (no URS: 15.0%; URS without biopsy: 18.4%; URS with biopsy: 21.9%). Meanwhile, a single postoperative instillation of intravesical chemotherapy has been shown to be associated with a reduced bladder recurrence risk after RNU compared with no instillation (hazard ratio 0.51, 95% confidence interval 0.32–0.82). Currently, there are no data on the value of a single postoperative intravesical instillation after ureteroscopy. Conclusions: Although based on limited retrospective data, performing URS seems to be associated with a higher risk of bladder recurrences. Future studies are warranted to assess the influence of other surgical factors as well as the role of URS biopsy or immediate postoperative intravesical chemotherapy after URS for UTUC. Patient summary: In this paper, we review recent findings on bladder recurrences after upper tract surgery for upper urinary tract urothelial carcinoma.

Published
2023
Full Text
View/download PDF

17. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Author

Rouprêt, Morgan, Seisen, Thomas, Birtle, Alison J., Capoun, Otakar, Compérat, Eva M., Dominguez-Escrig, José L., Gürses Andersson, Irene, Liedberg, Fredrik, Mariappan, Paramananthan, Hugh Mostafid, A., Pradere, Benjamin, van Rhijn, Bas W.G., Shariat, Shahrokh F., Rai, Bhavan P., Soria, Francesco, Soukup, Viktor, Wood, Robbert G., Xylinas, Evanguelos N., Masson-Lecomte, Alexandra, and Gontero, Paolo

Published
2023
Full Text
View/download PDF

18. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

Author

Beijert, Irene J., Cheng, Liang, Liedberg, Fredrik, Plass, Karin, Williamson, Sean R., Gontero, Paolo, Ribal, Maria J., Babjuk, Marko, Black, Peter C., Kamat, Ashish M., Algaba, Ferran, Berman, David M., Hartmann, Arndt, Masson-Lecomte, Alexandra, Rouprêt, Morgan, Lopez-Beltran, Antonio, Samaratunga, Hemamali, Shariat, Shahrokh F., Mostafid, A. Hugh, Varma, Murali, Shen, Steven, Burger, Maximilian, Tsuzuki, Toyonori, Palou, Joan, Compérat, Eva M., Sylvester, Richard J., van der Kwast, Theo H., van Rhijn, Bas W.G., and Downes, Michelle R.

Published
2023
Full Text
View/download PDF

20. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A.L.M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N'Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas.W.G.

Published
2023
Full Text
View/download PDF

22. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration

Author

Lonati , Chiara, Afferi, Luca, Mari, Andrea, Minervini, Andrea, Krajewski, Wojciech, Borghesi, Marco, Schulz, Gerald B., Rink, Michael, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Martini, Alberto, Necchi, Andrea, Contieri, Roberto, Hurle, Rodolfo, Umari, Paolo, Zamboni, Stefania, Simeone, Claudio, Soria, Francesco, Marra, Giancarlo, Gontero, Paolo, Teoh, Jeremy Yuen-Chun, Klatte, Tobias, Bajeot, Anne-Sophie, Roumiguié, Mathieu, Rouprêt, Morgan, Masson-Lecomte, Alexandra, Laukhtina, Ekaterina, Valiquette, Anne Sophie, Mir, M. Carmen, Antonelli, Alessandro, Einerhand, Sarah M. H., Hendricksen, Kees, Carando, Roberto, Fankhauser, Christian D., Baumeister, Philipp, Mattei, Agostino, Shariat, Shahrokh F., and Moschini, Marco

Published
2022
Full Text
View/download PDF

23. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Maxim Bruins, H., Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., A.L.M. Kiemeney, Lambertus, Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N'Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas.W.G.

Published
2022
Full Text
View/download PDF

27. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration

Author

Lonati, Chiara, Baumeister, Philipp, Afferi, Luca, Mari, Andrea, Minervini, Andrea, Krajewski, Wojciech, Azizi, Sosan, Hendricksen, Kees, Martini, Alberto, Necchi, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Tafuri, Alessandro, Antonelli, Alessandro, Cerruto, Maria Angela, Rouprêt, Morgan, Masson-Lecomte, Alexandra, Laukhtina, Ekaterina, D’Andrea, David, Shariat, Shahrokh F., Soria, Francesco, Marra, Giancarlo, Gontero, Paolo, Contieri, Roberto, Hurle, Rodolfo, Valiquette, Anne Sophie, Mir, M. Carmen, Zamboni, Stefania, Simeone, Claudio, Klatte, Tobias, Teoh, Jeremy Yuen-Chun, Yoshida, Soichiro, Fujii, Yasuhisa, Carando, Roberto, Schulz, Gerald B., Mordasini, Livio, Mattei, Agostino, and Moschini, Marco

Published
2022
Full Text
View/download PDF

29. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)

Author

Leon, P., Saint, F., Audenet, F., Roumiguié, M., Allory, Y., Loriot, Y., Masson-Lecomte, A., Pradère, B., Seisen, T., Traxer, O., Xylinas, E., Roupret, M., and Neuzillet, Y.

Published
2022
Full Text
View/download PDF

32. Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered.

Author

Gabriel, Pierre-Etienne, Pignot, Géraldine, Baboudjian, Michael, Lebacle, Cédric, Chamouni, Alexandre, Lechevallier, Eric, Irani, Jacques, Tillou, Xavier, Waeckel, Thibaut, Monges, Arnaud, Walz, Jochen, Gravis, Gwenaelle, Duperron, Céline, Carpentier, Xavier, Klein, Clément, and Masson-Lecomte, Alexandra

Subjects
NON-muscle invasive bladder cancer, SURVIVAL rate, DATABASES, HEMATURIA, BLADDER
Abstract

Purpose: To report the oncological outcomes and the tolerance between 6 instillations and more than 6 cycles of hyperthermic intravesical chemotherapy(HIVEC) in patients with non-muscle invasive bladder cancer(NMIBC). Methods: This is a multicenter retrospective study from a national database including 9 expert centers. All patients treated with HIVEC between 2016 and 2023 for NMIBC were included. Patients were classified into two groups according to the total number of HIVEC instillations, including induction plus maintenance. Kaplan-Meier curves were computed to present survival outcomes. Results: 261 patients with a median follow-up of 25.5 months were included. 199(76.2%) and 62(23.8%) were treated by 6 and more than 6 cycles of HIVEC, respectively. The 2-years RFS(40.2% vs. 34.4%,p = 0.3) and the 2-years PFS(86% vs. 87%,p = 0.85) were similar between group treated with 6 and more than 6 instillations. 2-years CSS and OS were also similar between both groups. Univariate Cox regression showed no association between the number of bladder instillation and RFS (HR = 1.2 95%CI[0.8–1.84], p = 0.3) or PFS (HR = 0.8 95%CI[0.29–2.02], p = 0.2). In the group treated with more than 6 cycles, 2-years RFS and 2-years PFS were similar between patients who received induction plus maintenance compared to those treated with induction only. Finally, hematuria and urinary burning were significantly higher in the group treated by more than 6 cycles (21% vs. 8.5%(p < 0.01),and 29% vs. 17% (p = 0.03), respectively). Serious side effects(grade ≥ 3) are rare(3.1%) and similar in both groups. Conclusions: Results show no significant difference in two years RFS, PFS, CSS and OS according to number of instillations received, while toxicity profile seems better in the group receiving six instillations only. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment

Author

Roumiguié, Mathieu, Compérat, Eva, Chaltiel, Léonor, Nouhaud, François Xavier, Verhoest, Gregory, Masson-Lecomte, Alexandra, Colin, Pierre, Audenet, François, Houédé, Nadine, Larré, Stéphane, Xylinas, Evanguelos, Brunelle, Serge, Piana-Thomassin, Jeanne, Cotte, Juliette, Pignot, Géraldine, Neuzillet, Yann, and Rouprêt, Morgan

Published
2021
Full Text
View/download PDF

35. Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels

Author

Mertens, L.S., primary, Bruins, H.M., additional, Contieri, R., additional, Babjuk, M., additional, Bhavan, R., additional, Carrion Puig, A., additional, Dominguez Escrig, J.L., additional, Gontero, P., additional, Van Der Heijden, A.G., additional, Liedberg, F., additional, Mariappan, P., additional, Masson-Lecomte, A., additional, Meijer, R.P., additional, Mostafid, H., additional, Neuzillet, Y., additional, Pradere, B., additional, Van Rhijn, B.W.G., additional, Roupret, M., additional, Seisen, T., additional, Soria, F., additional, Viktor, S., additional, Thalmann, G., additional, Xylinas, E., additional, and Witjes, F., additional

Published
2024
Full Text
View/download PDF

36. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study

Author

Gontero, P., primary, Soria, F., additional, Babjuk, M., additional, Burger, M., additional, Comperat, E., additional, Mostafid, H., additional, Palou Redorta, J., additional, Roupret, M., additional, Van Rhijn, B.W., additional, Zigeuner, R., additional, Shariat, S.F., additional, Cohen, D., additional, Masson-Lecomte, A., additional, Xylinas, E., additional, Mariappan, P., additional, Rai, B.P., additional, Capoun, O., additional, Soukup, V., additional, Thalmann, G., additional, Pradere, B., additional, Seisen, T., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, and Sylvester, R.J., additional

Published
2024
Full Text
View/download PDF

37. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer

Author

Contieri, R., primary, Beijert, I., additional, Martini, A., additional, Camperat, E.M., additional, Hernandez, V., additional, Bruins, H.M., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, Masson-Lecomte, A., additional, Cohen, D., additional, Mostafid, H., additional, Shariat, S.F., additional, Roupret, M., additional, Pradere, B., additional, Zigeuner, R., additional, Soria, F., additional, Soukup, V., additional, Palou Redorta, J., additional, Capoun, O., additional, Burger, M., additional, Gontero, P., additional, Sylvester, R., additional, Mertens, L., additional, and Van Rhijn, B.W.G., additional

Published
2024
Full Text
View/download PDF

38. Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies

Author

Leonard Lugand, Guillaume Mestrallet, Rebecca Laboureur, Clement Dumont, Fatiha Bouhidel, Malika Djouadou, Alexandra Masson-Lecomte, Francois Desgrandchamps, Stephane Culine, Edgardo D. Carosella, Nathalie Rouas-Freiss, and Joel LeMaoult

Subjects
spheroid, renal cell carcinoma, immune checkpoint inhibitors, standardization, PD-1, heterogeneity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost in the classically used 2D models along with their relative simplicity and handiness have made them the most studied 3D tumor model. Their application as a theranostic tool or as a means to study tumor-host interaction is now well-established in various cancers. However, their use in the field of Renal Cell Carcinoma (RCC) remains very limited. The aim of this work is to present methods to implement a basic RCC spheroid model. These methods cover the steps from RCC tumor dissociation to spheroid infiltration by immune cells. We present a protocol for RCC dissociation using Liberase TM and introduce a culture medium containing Epithelial Growth Factor and Hydrocortisone allowing for faster growth of RCC primary cells. We show that the liquid overlay technique allows for the formation of spheroids from cell lines and from primary cultures. We present a method using morphological criteria to select a homogeneous spheroid population based on a Fiji macro. We then show that spheroids can be infiltrated by PBMCs after activation with OKT3 or IL-15. Finally, we provide an example of application by implementing an immune spheroid killing assay allowing observing increased spheroid destruction after treatment with PD-1 inhibitors. Thus the straightforward methods presented here allow for efficient spheroid formation for a simple RCC 3D model that can be standardized and infused with immune cells to study immunotherapies.

Published
2022
Full Text
View/download PDF

39. Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database

Author

Pignot, G., primary, Baboudjian, M., additional, Masson-Lecomte, A., additional, Lebacle, C., additional, Tillou, X., additional, Waeckel, T., additional, Duperron, C., additional, Monges, A., additional, Alezra, E., additional, Irani, J., additional, Lechevallier, E., additional, Gravis, G., additional, and Walz, J., additional

Published
2023
Full Text
View/download PDF

47. Do current definitions of BCG failure/ BCG unresponsive NMIBCs correlate with disease progression? Results of an individual patient data validation international multi-center retrospective study

Author

P. Gontero, F. Soria, M. Babjuk, M. Burger, E.M. Comperat, H. Mostafid, J. Palou Redorta, M. Roupret, B.W. Van Rhijn, R. Zigeuner, S.F. Shariat, D. Cohen, A. Masson-Lecomte, V. Hernandez, E. Xylinas, O. Capoun, G. Thalmann, B. Pradere, E. Linares, V. Soukup, T. Seisen, J. Dominguez-Escrig, F. Liedberg, and R.J. Sylvester

Subjects
Urology
Published
2023

48. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum

Author

Irene J. Beijert, Anouk E. Hentschel, Johannes Bründl, Eva M. Compérat, Karin Plass, Oscar Rodríguez, Jose D. Subiela Henríquez, Virginia Hernández, Enrique de la Peña, Isabel Alemany, Diana Turturica, Francesca Pisano, Francesco Soria, Otakar Čapoun, Lenka Bauerová, Michael Pešl, H. Maxim Bruins, Willemien Runneboom, Sonja Herdegen, Johannes Breyer, Antonin Brisuda, Ana Calatrava, José Rubio-Briones, Maximilian Seles, Sebastian Mannweiler, Judith Bosschieter, Venkata R.M. Kusuma, David Ashabere, Nicolai Huebner, Juliette Cotte, Laura S. Mertens, Francesco Claps, Alexandra Masson-Lecomte, Fredrik Liedberg, Daniel Cohen, Luca Lunelli, Olivier Cussenot, Soha El Sheikh, Dimitrios Volanis, Jean-François Côté, Morgan Rouprêt, Andrea Haitel, Shahrokh F. Shariat, A. Hugh Mostafid, Jakko A. Nieuwenhuijzen, Richard Zigeuner, Jose L. Dominguez-Escrig, Jaromir Hacek, Alexandre R. Zlotta, Maximilian Burger, Matthias Evert, Christina A. Hulsbergen-van de Kaa, Antoine G. van der Heijden, Lambertus A.L.M. Kiemeney, Viktor Soukup, Luca Molinaro, Paolo Gontero, Carlos Llorente, Ferran Algaba, Joan Palou, James N'Dow, Maria J. Ribal, Theo H. van der Kwast, Marko Babjuk, Richard J. Sylvester, Bas.W.G. van Rhijn, Beijert, Irene J, Hentschel, Anouk E, Bründl, Johanne, Compérat, Eva M, Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D, Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johanne, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R M, Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S, Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrio, Côté, Jean-Françoi, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F, Mostafid, A Hugh, Nieuwenhuijzen, Jakko A, Zigeuner, Richard, Dominguez-Escrig, Jose L, Hacek, Jaromir, Zlotta, Alexandre R, Burger, Maximilian, Evert, Matthia, Hulsbergen-van de Kaa, Christina A, van der Heijden, Antoine G, Kiemeney, Lambertus A L M, Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlo, Algaba, Ferran, Palou, Joan, N'Dow, Jame, Ribal, Maria J, van der Kwast, Theo H, Babjuk, Marko, Sylvester, Richard J, van Rhijn, Bas W G, Urology, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, and Other Research

Subjects
Urology, Bladder, Grade, Carcinoma, Cancer, Carcinomas, G3, Non–muscle-invasive, Stage Ta, Urothelial, World Health Organization, Oncology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Radiology, Nuclear Medicine and imaging, Surgery
Abstract

Contains fulltext : 294430.pdf (Publisher’s version ) (Open Access) BACKGROUND: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component. The European Association of Urology (EAU) NMIBC guidelines recently changed the risk stratification for Ta G3 from high risk to intermediate, high, or very high risk. However, prognostic studies on Ta G3 carcinomas are limited and inconclusive. OBJECTIVE: To evaluate the prognostic value of categorizing Ta G3 compared to Ta G2 and T1 G3 carcinomas. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for 5170 primary Ta-T1 bladder tumors from 17 hospitals were analyzed. Transurethral resection of the tumor was performed between 1990 and 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to recurrence and time to progression were analyzed using cumulative incidence functions, log-rank tests, and multivariable Cox-regression models with interaction terms stratified by institution. RESULTS AND LIMITATIONS: Ta G3 represented 7.5% (387/5170) of Ta-T1 carcinomas of which 42% were classified as intermediate risk. Time to recurrence did not differ between Ta G3 and Ta G2 (p = 0.9) or T1 G3 (p = 0.4). Progression at 5 yr occurred for 3.6% (95% confidence interval [CI] 2.7-4.8%) of Ta G2, 13% (95% CI 9.3-17%) of Ta G3, and 20% (95% CI 17-23%) of T1 G3 carcinomas. Time to progression for Ta G3 was shorter than for Ta G2 (p

Published
2023

49. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum

Author

I.J. Beijert, A.E. Hentschel, J. Bründl, E.M Compérat, K. Plass, O. Rodríguez, J.D. Subiela Henríquez, V. Hernández, E. De La Peña, I. Alemany, D. Turturica, F. Pisano, F. Soria, O. Čapoun, L. Bauerová, M. Pešl, H.M. Bruins, W. Runneboom, S. Herdegen, J. Breyer, A. Brisuda, A. Calatrava, J.. Rubio-Briones, M. Seles, S. Mannweiler, J. Bosschieter, V.R.M. Kusuma, D. Ashabere, N. Huebner, J. Cotte, L.S Mertens, A. Masson-Lecomte, F. Liedberg, D. Cohen, L. Lunelli, O. Cussenot, S. El Sheikh, D. Volanis, J. Côté, M. Rouprêt, A. Haitel, S.F. Shariat, A.H. Mostafid, J.A. Nieuwenhuijzen, R. Zigeuner, J.L. Dominguez-Escrig, J. Hacek, A.R. Zlotta, M. Burger, M. Evert, C.A. Hulsbergen - Van De Kaa, A.G. Van Der Heijden, L.A.L.M. Kiemeney, V. Soukup, L. Molinaro, P. Gontero, C. Llorente, F. Algaba, J. Palou, J. N’Dow, M.J. Ribal, T.H. Van Der Kwast, M. Babjuk, R.J. Sylvester, and B.W.G. Van Rhijn

Subjects
Urology
Published
2022

50. Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway

Author

T.-R. Dobé, Y. Belhadj, C. Michel, M. Djouadou, A. Bouchardi, C. Liron, C. Bento, A. Aregui, P. Meria, A. Thevenot, B. Plaud, S. Culine, P. Mongiat-Artus, F. Desgrandchamps, and A. Masson-Lecomte

Subjects
Postoperative Complications, Urinary Bladder Neoplasms, Urology, Urinary Bladder, Humans, Cystectomy, Neoadjuvant Therapy, Retrospective Studies
Abstract

The effect of ERAS protocols in a population of radical cystectomy (RC) patients fit for neoadjuvant chemotherapy has not been specifically explored.To compare perioperative outcomes of open RC according to the application of an ERAS protocol in a population of patients treated by cisplatin-based NAC.All consecutive patients treated by NAC and RC between 2016 and 2019 were included. The ERAS pathway was implemented in June 2018 and followed the EAU recommendations. All data were prospectively collected. Patients' characteristics, operative outcomes, length of stay (LOS), complication rate according to Clavien-Dindo and pathological results were compared between pre- and post-ERAS. Statistical analysis was performed using R.In total, 79 patients were included, 29 in the ERAS group and 50 in the non-ERAS group. A median number of 19 out of 22 ERAS criteria were followed. Mean number of NAC cycles was 4.45 vs. 4.79 in the pre- and post-ERAS groups respectively (P=0.24). Median time between NAC and RC was 3.8months. Thirty-eight percent vs. 48% of patients received an ileal neobladder in the pre- and post-ERAS group respectively (P=0.51). No differences were observed regarding operative time, blood loss or operative transfusion rates. LOS was drastically reduced in the ERAS period (18.94 vs. 12.10days, P0.001) as well as major (Clavien 2) complications rate (65% vs. 28%, P=0.004).ERAS drastically reduced the LOS and the rate of high-grade complications and can be effectively applied to patients receiving NAC without delaying RC.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results